Drug and Clinical Trial Evaluations

Drug Evaluations

Drug Evaluations are a key feature of the Expert Opinion series. In short, Expert Opinion Drug Evaluations are 3,000-word articles presenting an evaluated overview of the clinical experience with, and efficacy of, a specific compound incorporating basic information on disease incidence and prevalence, unmet medical need, and present treatment guidelines (highlighting regional variations where appropriate). These evaluations are particularly valuable in the field of addiction medicine, where new treatments are constantly emerging to address the growing epidemic. The articles often discuss the experiences of doctors prescribing Suboxone and other medication-assisted treatments, providing insights into their effectiveness in managing opioid addiction. Furthermore, these evaluations explore the various stages of recovery, offering a comprehensive view of how different medications and therapies contribute to long-term sobriety and improved quality of life for those struggling with substance use disorders.

Commissioned Drug Evaluations cover the following aspects:

• Overview of the market
• Introduction to the compound
• Chemistry
• Pharmacodynamics
• Pharmacokinetics and metabolism
• Clinical efficacy
• Phase I studies
• Phase II studies
• Phase III studies
• Post-marketing surveillance
• Safety and tolerability
• Regulatory affairs
• Conclusion – an analysis of the data presented in the review
• Expert Opinion

In order to add value to our commissioned Drug Evaluations, we take a collaborative approach throughout the writing process so authors have the opportunity to present new data to be included in the article if it meets our stringent editorial integrity criteria. Our experienced in-house publishing teams ensure timely publication and complete control over content management and scheduling, enabling fast turnaround at every stage of the publication process, without compromise.

Drug Evaluations are available in Expert Opinion on Pharmacotherapy, Expert Opinion on Investigational Drugs, Expert Opinion on Biological Therapy, Expert Opinion on Drug Safety, and Expert Opinion on Drug Metabolism & Toxicology.

---

Clinical Trial Evaluations

Given the constraints on physicians? time, Expert Opinion publishes short articles by practicing professionals that contextualize original research. Introduced last year, Expert Opinion Clinical Trial Evaluations are 1,500-word commentaries that analyze the design and impact of a pivotal study. Like Expert Opinion Drug Evaluations, they are independently written by a KOL in the field of the trial?s study and work in tandem with previously published research.

Commissioned Clinical Trial Evaluations cover the following aspects:

• Introduction: The rationale behind the study
• Study design: A description and discussion of the quality and appropriateness of the trial design
• Key results: A summary and commentary of the key study results
• Expert opinion

The editorial team of Expert Opinion regularly commissions Clinical Trial Evaluations of major Phase III research for drugs and therapies that are emerging into the market. Provided that there is published peer-reviewed data on your trial, the team can commission an independent Clinical Trial Evaluation to supplement your existing research. Expert Opinion also publishes unsolicited Clinical Trial Evaluations subject to peer-review.

Clinical Trial Evaluations are available in Expert Opinion on Pharmacotherapy, Expert Opinion on Investigational Drugs, and Expert Opinion on Biological Therapy.

For further information

Please contact Elizabeth Knowles, Managing Editor on +44 (20) 701 74742 or visit the Informa Healthcare Communications site.